<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835365</url>
  </required_header>
  <id_info>
    <org_study_id>OBADE</org_study_id>
    <nct_id>NCT02835365</nct_id>
  </id_info>
  <brief_title>Observational Study on Patients With Baclofen Treatment for Alcohol-dependence in France</brief_title>
  <acronym>OBADE</acronym>
  <official_title>Observational Study on Patients With Baclofen Treatment for Alcohol-dependence in French Gastro and Hepatology Departments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Intercommunal Creteil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association Nationale des Hépato-Gastroentérologues des Hôpitaux Généraux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Intercommunal Creteil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Baclofen is an agonist of the amino-butyricum B (GABA-B) receptor used for a long time in
      neurology to treat spastic contracture. Several clinical studies have suggested its efficacy
      in the treatment of alcohol-dependence in low, even in case of cirrhosis and high dose.
      French drug authority has authorized its use in 2012 whereas the l'European Association for
      the Study of the Liver recommends to perform additional studies on this indication.

      The goal of this observational study is to evaluate the use of baclofen for
      alcohol-dependence in real life care as well its efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Numerous centers of the French research group of the national association of the
      hepatologists and gastroenterologists from general hospitals (ANGH) will be part of this
      study. Patients treated with baclofen for alcohol -dependence will be enroll prospectively
      from 2014 and retrospectively if they were treated between 2012 and 2014. The reported
      alcohol consumption, biological markers of excessive alcohol, initial and usual baclofen
      dosage, blood balofen dosage as well as clinical data will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Target population</measure>
    <time_frame>at inclusion</time_frame>
    <description>Demographic and clinical characteristics of patients who take baclofen for alcohol addiction: mean age, alcohol consumption, child pugh score, etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>baclofen posology</measure>
    <time_frame>at inclusion, at 3, 6 and 12 months of follow-up</time_frame>
    <description>used baclofen posology will be recorded to determine the posology scheme to treat patients with or without cirrhosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol consumption</measure>
    <time_frame>at inclusion, at 3, 6 and 12 months of follow-up</time_frame>
    <description>Evolution of the alcohol consumption in patients under baclofen therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological markers of alcohol consumption</measure>
    <time_frame>at inclusion, at 3, 6 and 12 months of follow-up</time_frame>
    <description>Evolution of the biological markers of alcohol consumption in patients under baclofen therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>baclofen tolerance</measure>
    <time_frame>at 3, 6 and 12 months of follow-up</time_frame>
    <description>Description of the side effects under baclofen therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baclofen dosage</measure>
    <time_frame>at 3, 6 and 12 months of follow-up</time_frame>
    <description>Blood baclofen dosage under baclofen treatment, if available</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Alcohol Drinking</condition>
  <condition>Cirrhosis</condition>
  <condition>Alcohol Withdrawal</condition>
  <arm_group>
    <arm_group_label>patients treated with baclofen</arm_group_label>
    <description>Patients treated with baclofen to diminish their alcohol consumption in the ANGH centers will be enrolled</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      biologic sample to dose the blood baclofenemia
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Any patients older than 18 years old and who received a baclofen therapy for
        alcohol-dependance after 2012 in a participating site is eligible. The referral physician
        must inform the patient. Only patients who give their oralm accceptance will be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients older than 18 years old

          -  patient treated with baclofen therapy after 2012 for alcoholo-dependance

        Exclusion Criteria:

          -  Baclofen therapy before 2012

          -  patient who refuse to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camille barrault, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHI Créteil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre hospitalier yves LEFOLL</name>
      <address>
        <city>Saint Brieux</city>
        <state>Côtes d'Armor</state>
        <zip>22023</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <state>Franche-Comté</state>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Béziers</name>
      <address>
        <city>Béziers</city>
        <state>Hérault</state>
        <zip>34525</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital saint denis</name>
      <address>
        <city>Saint denis</city>
        <state>Ile de France</state>
        <zip>93205</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Orleans</name>
      <address>
        <city>Orleans</city>
        <state>Loiret</state>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GHPSO Creil-Senlis</name>
      <address>
        <city>Creil</city>
        <state>Oise</state>
        <zip>60109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH meaux</name>
      <address>
        <city>Meaux</city>
        <state>Seine et marne</state>
        <zip>77100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI CRETEIL addictology</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2016</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Intercommunal Creteil</investigator_affiliation>
    <investigator_full_name>Camille Barrault</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>baclofen</keyword>
  <keyword>alcohol</keyword>
  <keyword>withdrawal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

